Janux Therapeutics, Inc.

NASDAQ:JANX

Biotechnology

Healthcare
$10.31 -1.74%

-$0.25 today

Market cap
$630.80M
Beta
2.52
P/E (TTM)
-7.6
EPS (TTM)
-$1.83
52W Low $12.12High $35.34

Volume 0.98M

Average 1.02M

JANX EPS (Basic)

Net income attributable to common shareholders divided by the weighted average basic shares outstanding.

Janux Therapeutics, Inc.NASDAQ: JANX

EPS (Basic) · Q1 FY2026 · quarter ended Mar 2026

EPS (Basic) remains negative

Q1 FY2026 EPS (Basic) was -$0.39, compared with -$0.38 a year earlier. Trailing-twelve-month EPS (Basic) was -$1.84.

Context

  • EPS (Basic) grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether EPS (Basic) reaches the consensus estimate from 13 analysts of -$1.64 (+10.6%) for the fiscal year ending Dec 2026, a step up from the -43.0% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-$0.39+23.5% QoQ
Last fiscal yearDec 2025
-$1.83-43.0% YoY
LTMMar 2026
-$1.84-35.3% YoY
EPS (Basic) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-2.6%+54.3%+56.9 pp
1 year-43.0%+10.6%+53.6 pp
3-year CAGR———
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EPS (Basic) history

USD · from the income statement

Latest · FY2025
(1.83) USD
Year-over-year change
-43.0%
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EPS (Basic) vs competitors

How JANX compares with its peers on the latest reported figures

  • Peers report in different currencies, so EPS (Basic) is compared through growth and rates rather than absolute size.
  • Its year-over-year change of -35.3% is the 7th highest of 10, against a peer median of -23.6%.
JANX Competitors
EPS (Basic) for JANX and competitors
Company Period LTM YoY 3-year CAGR
LEGNLegend Biotech CorporationLTM Sep 2026-$0.01 USD+99.2%—
CTMXCytomX Therapeutics, Inc.LTM Mar 2026-$0.36 USD-172.2%—
CMPXCompass Therapeutics, Inc.LTM Mar 2026-$0.43 USD-5.9%—
MGNXMacroGenics, Inc.LTM Mar 2026-$1.1 USD-23.6%—
IMTXImmatics N.V.LTM Mar 2026-€1.71 EUR-1314.4%—
JANXJanux Therapeutics, Inc.LTM Mar 2026-$1.84 USD-35.3%—
IMNMImmunome, Inc.LTM Sep 2026-$2.65 USD+10.2%—
CGEMCullinan Therapeutics, Inc.LTM Mar 2026-$3.75 USD-21.4%—
CLDXCelldex Therapeutics, Inc.LTM Sep 2026-$4.31 USD-27.5%—
STROSutro Biopharma, Inc.LTM Mar 2026-$307.72 USD-936.1%—
VRXAVeraxa Biotech Holding AG—— ——
Peer median (excluding JANX) —-23.6%—

Competitors are the stored peer set for JANX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue3.64M8.61M8.08M10.59M10M
Cost of Revenue26.24M841K1.96M2.06M2.03M
Gross Profit(22.6M)7.77M6.13M8.53M7.97M
Gross Margin-621.4%90.2%75.8%80.5%79.7%
Research & Development26.24M53.44M54.92M68.39M125.9M
Selling, General & Admin10.33M22.26M26.14M41.05M41.77M
Operating Expenses10.33M74.86M79.11M107.38M165.64M
Depreciation & Amortization113K841K1.96M2.06M2.03M
EBITDA(32.56M)(62.22M)(56.34M)(66.93M)(111.6M)
EBITDA Margin-895.2%-722.5%-697.0%-632.2%-1116.0%
Operating Income(32.93M)(67.09M)(72.98M)(98.85M)(157.67M)
Operating Margin-905.4%-779.0%-902.9%-933.6%-1576.7%
Interest Income257K4.03M14.69M29.85M44.04M
Interest Expense00000
Other Income / Expenses257K4.03M14.69M29.85M44.04M
Income Before Tax(32.67M)(63.06M)(58.29M)(68.99M)(113.63M)
Pre-Tax Margin-898.3%-732.2%-721.2%-651.6%-1136.3%
Income Tax Expense00000
Net Income(32.67M)(63.06M)(58.29M)(68.99M)(113.63M)
Net Margin-898.3%-732.2%-721.2%-651.6%-1136.3%
EPS (Basic)(0.79)(1.52)(1.32)(1.28)(1.83)
EPS (Diluted)(0.79)(1.52)(1.32)(1.28)(1.83)
Weighted Avg Shares41.24M41.47M44.02M53.75M61.97M
Weighted Avg Shares (Diluted)41.24M41.47M44.02M53.75M61.97M

Janux Therapeutics, Inc.

NASDAQ:JANX

Intrinsic Alpha fair value

Locked

Current Price

$10.31

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.